PTCE Pharmacy Connect | Pharmacy Times

The Latest Updates and Pharmacist Perspectives on RET Inhibitors in Non-Small Cell Lung Cancer | PTCE Pharmacy Connect

Educational Objectives
Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer
Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence
 
Faculty
Lauren Ledbetter, PharmD, BCOP
Clinical Pharmacy Specialist, Thoracic Medical Oncology
The James Cancer Hospital at The Ohio State University
Columbus, Ohio
 
Moderator
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Clinical Pharmacy Manager
University of Kansas Cancer Center
Division of Hematologic Malignancies & Cellular Therapeutics
 
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-24-304-H01-P. The activity is available for CE credit through October 31, 2025.
 
This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.

Alleviating Patient Burden in Acne: Utilizing Ceramides to Address Skin Barrier Dysfunction | PTCE Pharmacy Connect

Educational Objectives
Review challenges that impact optimal treatment of skin barrier dysfunction in patients with acne who are seeking OTC care
List strategies to individualize patient care and improve recommendations for patients with acne experiencing skin barrier dysfunction
Faculty:
Robin Laird
Patient Advocate
Los Angeles, California
 
Mary Barna Bridgeman, PharmD, BCPS, BCGP
Clinical Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
 
Internal Medicine Pharmacist
Robert Wood Johnson University Hospital-New Brunswick
New Brunswick, New Jersey
Mary Barna Bridgeman, PharmD, BCPS, BCGP, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.05 CEU) under the ACPE universal activity numbers 0290-0000-24-128-H01-P and 0290-0000-24-128-H01-T. The activity is available for CE credit through April 29, 2025.
This activity is supported by an educational grant from CeraVe. 

Challenges in Treatment of Desmoid Tumors and Managed Care Solutions | PTCE Pharmacy Connect

 
Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.
Title: Challenges in Treatment of Desmoid Tumors and Managed Care Solutions
Educational Objectives
• Recall the key characteristics of desmoid tumors (DT), including presentation, frequency, genetic mutations, development, and outlook for individual patients
• Outline practical solutions to improve managed care-driven communication with health care providers and address the clinical and financial burden of unresectable, recurrent DT
Moderator:
Laura Bobolts, PharmD, BCOP
Senior Vice President of Clinical Strategy and Growth
OncoHealth
Plantation, Florida
 
Faculty:
Christy Harris, PharmD, BCOP, FHOPA    
Clinical Pharmacy Specialist                                                               
Dana-Farber Cancer Institute
Associate Professor
Massachusetts College of Pharmacy and Health Sciences
Boston, Massachusetts
 
Christy Harris, PharmD, BCOP, FHOPA and Laura Bobolts, PharmD, BCOP have no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-421-H01-P. The activity is available for CE credit through February 28, 2024.
This activity is supported by an educational grant from SpringWorks Therapeutics.
 

Examining Patient Burden in Atopic Dermatitis: Understanding Treatment Barriers and Optimal Use of OTC Skin Care Products, featuring a Caregiver Perspective | PTCE Pharmacy Connect

To claim CE credit for this activity, please follow this link: www.pharmacytimes.org/atopic-derm-podcast-630
Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.
Educational Objectives
Review patient barriers that impact optimal treatment of patients with atopic dermatitis (AD) who are seeking OTC care
List strategies to individualize patient care and improve recommendations for AD
Moderator:
Mary Bridgeman, PharmD, BCPS, BCGP
Clinical Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
 
Internal Medicine Clinical Pharmacist
Robert Wood Johnson University Hospital
New Brunswick, New Jersey
 
Faculty & Caregiver:
Ashley Ellis, PharmD, MBA, CDECS
ImPAcT Director & Assistant Professor
The University of Tennessee Health Science Center
Department of Clinical Pharmacy and Translation Science College of Pharmacy
Memphis, Tennessee
 
Mary Bridgeman, PharmD, BCPS, BCGP has no financial relationships with commercial interests to disclose.
Ashley Ellis, PharmD, MBA, CDECS, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: Researcher AHRQ “Tennessee Heart Health Network” funding in form of salary release dollars
Consultant: Global Parents for Eczema Research, Continuing Education Alliance, McGraw Hill
 
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-268-H01-P and 0290-0000-23-268-H01-T. The activity is available for CE credit through June 30, 2024.
This activity is supported by an educational grant from CeraVe and La Roche-Posay.
Brought to you in partnership with the National Eczema Association.

Continuing the Conversation: A Review of Targeted Therapies for Early-Stage Breast Cancer | PTCE Pharmacy Connect

Educational Objectives
Outline the place in therapy for targeted therapies based on patient-specific factors and subtype of early-stage breast cancer
Recognize methods to improve patient treatment selection while mitigating toxicities in patients with early-stage breast cancer
Faculty:
Allison R. Butts, PharmD, BCOP
Pharmacist Manager, Oncology
Breast Oncology Clinical Pharmacy Specialist
Acute Care Pharmacy Services
UK HealthCare- Markey Cancer
Lexington, Kentucky
 
Director, PGY2 Oncology Residency Program
UK HealthCare
Lexington, Kentucky
Allison R. Butts, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: AstraZeneca; BeyondSpring (one-time advisory boards)
Moderator:
Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth
Laura R. Bobolts, PharmD, BCOP, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-239-H01-P. The activity is available for CE credit through May 31, 2024.
This activity is supported by independent medical educational grants from AstraZeneca; Merck & Co., Inc.; Puma Biotechnology Inc., and Lilly.

Treatment of Duchenne Muscular Dystrophy: Updates in Disease-Modifying Drugs | PTCE Pharmacy Connect

Educational Objectives
Recall the pathophysiology and clinical manifestations of Duchenne muscular dystrophy (DMD), as well as the burden of DMD and its impact on patient quality of life
List the latest updates for the safety and efficacy data of new and approved disease-modifying therapies in the treatment of DMD
 
Faculty:
Amanda Hickman, PharmD, MPH, MSCS
Central Support Pharmacist – Neuro/Psych/Sleep
Trellis Rx
Atlanta, Georgia
 
Moderator:
Jessica L. Kerr, PharmD, CDCES
Associate Dean – Office Professional and Student Affairs
Professor/Clinical Pharmacist
Southern Illinois University Edwardsville
School of Pharmacy
Edwardsville, Illinois
 
Amanda Hickman, PharmD, MPH, MSCS, and Jessica L. Kerr, PharmD, CDCES, have no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-613-H01-P. The activity is available for CE credit through December 22, 2023.
 
This activity is supported by an educational grant from Sarepta Therapeutics.

Exploring the Emerging Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell | PTCE Pharmacy Connect

Educational Objective:
Outline various challenges and uncertainties affecting the optimization of treatment with novel immunotherapeutic modalities for relapsed/refractory diffuse large B-cell lymphoma.
 
Faculty:
Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist - Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
 
Moderator:
Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth
Plantation, Florida
 
Victoria Nachar, PharmD, BCOP & Laura R. Bobolts, PharmD, BCOP, have no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-611-H01-P. The activity is available for CE credit through December 22, 2023.
 
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc; Genmab; and AbbVie, Inc.

Advances in the Treatment of Immune Thrombocytopenia: Strategies for Optimizing Clinical and Patient Outcomes | PTCE Pharmacy Connect

Educational Objectives
Outline current guideline recommendations and strategies pharmacists can implement for the management of immune thrombocytopenia (ITP)
Recall the efficacy and safety of emerging agents for the treatment of ITP
 
Moderator:
Anthony J. Perissinotti, PharmD, BCOP
To claim CE credit for this activity, please visit the link below:
https://www.pharmacytimes.org/courses/advances-in-the-treatment-of-immune-thrombocytopenia-strategies-for-optimizing-clinical-and-patient-outcomes
Hematology Clinical Pharmacist Specialist
Clinical Team Leader Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan – Michigan Medicine
Ann Arbor, Michigan
 
Faculty:
Lisa Charneski, PharmD, BCPS
Assistant Dean for Academic Affairs
Philadelphia College of Pharmacy
Associate Professor of Clinical Pharmacy
Department of Pharmacy Practice Saint Joseph’s University
Philadelphia, Pennsylvania
Anthony J. Perissinotti, PharmD, BCOP has the following relevant financial relationships with commercial interests to disclose:Consultant: AbbVie, BeiGene, Janssen
Lisa Charneski, PharmD, BCPS, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Melody, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEU) under the ACPE universal activity number 0290-0000-22-608-H01-P. The activity is available for CE credit through December 19, 2023.
 
This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.

Treatment Advancements in Atopic Dermatitis With JAK Inhibitors: Updates for Pharmacists | PTCE Pharmacy Connect

The educational objectives are:
• Review the pathophysiology of atopic dermatitis (AD) as well as the efficacy and safety data for topical JAK inhibitors that are approved and in development
• Discuss the role of pharmacists as a part of the care team for patients with AD as well as the key counseling points and monitoring parameters
 
Faculty: Dennis Williams
Moderator: Jamie McConaha

Continuing the Conversation: Exploring B-cell Maturation Antigen-Targeted Therapies and Managed Care Considerations for Patients With Multiple Myeloma | PTCE Pharmacy Connect

Educational Objectives
Discuss the differing classes of B-cell maturation antigen-directed therapy for multiple myeloma
Study the economic burden of multiple myeloma and cost-effective treatment strategies for B-cell maturation antigen-directed treatments
Faculty:
Joseph A. Kalis, PharmD, BCOP
Ambulatory Oncology Pharmacist
UCHealth Hematology/Oncology
Colorado Springs, Colorado
 
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Director, Pharmacy Cancer Care
Department of Pharmacy
Mayo Clinic
 
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine and Sciences
Rochester, Minnesota
 
Joseph A. Kalis, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:Speakers Bureau: Oncopeptides, GSK
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following financial relationships with commercial interests to disclose:Grant/Research Support: AstraZeneza, Janssen
Consultant: BeiGene
Speakers Bureau: Pfizer
 
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-359-H01-P. The activity is available for CE credit through July 29, 2023.
 
This educational activity is supported by an educational grant from GlaxoSmithKline.